Regeneron Pharmaceuticals (REGN) versus Its Rivals Financial Contrast
Regeneron Pharmaceuticals (NASDAQ: REGN) is one of 293 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Regeneron Pharmaceuticals to similar businesses based on the strength of its dividends, earnings, valuation, analyst recommendations, profitability, institutional ownership and risk.
This is a summary of current ratings for Regeneron Pharmaceuticals and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Regeneron Pharmaceuticals Competitors||756||3014||11127||227||2.72|
Regeneron Pharmaceuticals currently has a consensus target price of $492.57, indicating a potential upside of 11.71%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 35.14%. Given Regeneron Pharmaceuticals’ competitors stronger consensus rating and higher possible upside, analysts plainly believe Regeneron Pharmaceuticals has less favorable growth aspects than its competitors.
Earnings & Valuation
This table compares Regeneron Pharmaceuticals and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Regeneron Pharmaceuticals||$5.24 billion||$1.82 billion||44.27|
|Regeneron Pharmaceuticals Competitors||$258.58 million||$65.84 million||-6.88|
Regeneron Pharmaceuticals has higher revenue and earnings than its competitors. Regeneron Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Risk and Volatility
Regeneron Pharmaceuticals has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals’ competitors have a beta of 6.66, indicating that their average stock price is 566% more volatile than the S&P 500.
Insider and Institutional Ownership
67.4% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 51.0% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 10.8% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This table compares Regeneron Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Regeneron Pharmaceuticals Competitors||-5,620.59%||-452.72%||-42.36%|
Regeneron Pharmaceuticals beats its competitors on 7 of the 13 factors compared.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company’s marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.